A Phase 1, Single-center, Fixed-sequence, Open Label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Trial Profile

A Phase 1, Single-center, Fixed-sequence, Open Label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Tenapanor (Primary) ; Midazolam
  • Indications Heart failure; Hyperphosphataemia; Irritable bowel syndrome; Kidney disorders
  • Focus Pharmacokinetics
  • Sponsors Ardelyx; AstraZeneca
  • Most Recent Events

    • 22 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 May 2014 Status changed from not yet recruiting to recruiting; according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top